Investor Presentaiton
ESTELLE® – addressing women's unmet need and
improving women's contraceptive experience
Improving contraceptive experience
➤ Reliable contraceptive efficacy
➤ Excellent cycle control'
Proven superiority in comparison to
Ethinylestradiol containing COCs
➤Improved quality of life & high user
satisfaction
➤ Potential positive skin effect
➤ Low risk of drug-drug interaction²
Addressing unmet needs
Favorable safety profile
Low impact on all markers of
coagulation suggest low clotting risk
Minimal increase of triglycerides
➤ Minimal impact on glucose metabolism
➤Minimal impact on breast tissue
expected based on preclinical data³
1) Kaunitz et al,. Contraception 2022; Jensen et al., Contraception 2022; Archer et al., JCM 2022
2) Foidart et al., NAMS 2022
3) Gallez et al. Cancers 2021
Mithra Investor Presentation - November 2023
18View entire presentation